This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Sagent Pharmaceuticals Co (SGNT)

NASDAQ: Health Care

Company Cash Flow
Dec 2013 Dec 2012 Dec 2011 Dec 2010
Cash Flow From Operating Activities
Net Income (Loss) 29.59M -16.82M -26.42M -24.50M
Operating Gains/Losses -5.33M 3.82M 2.53M 1.48M
Extraordinary Gains / Losses 0.00 0.00 0.00 0.00
(Increase) Decrease In Receivables 1.65M -1.64M -11.60M -12.44M
(Increase) Decrease in Inventories 3.05M -5.62M -10.92M -11.58M
(Increase) Decrease In Other Current Assets 0.00 0.00 0.00 0.00
(Decrease) Increase In Payables 7.48M -10.55M 15.52M 13.18M
(Decrease) Increase In Other Current Liabilities 0.00 0.00 0.00 0.00
(Increase) Decrease In Other Working Capital 0.00 0.00 0.00 0.00
Other Non-Cash Items 9.50M 5.55M 3.38M 1.77M
Net Cash From Continuing Operations 49.55M -20.12M -20.42M -27.80M
Net Cash From Discontinued Operations 0.00 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities 49.55M -20.12M -20.42M -27.80M
Sale of Property, Plant & Equipment 0.00 0.00 0.00 0.00
Cash Used for Investing Activities
Sale of Short-Term Investments 0.00 0.00 0.00 0.00
Purchases of Property, Plant & Equipment -6.28M -3.36M -5.09M -2.18M
Acquisitions -13.02M -399.00K 139.00K -5.19M
Purchases of Short-Term Investments 0.00 0.00 0.00 0.00
Other Cash from Investing Activities 605.00K 23.00K 185.00K 100.00K
Cash Provided by Financing Activities
Net Cash From Investing Activities -97.16M 32.64M -79.60M -7.28M
Issuance of Debt 0.00 0.00 15.00M 16.21M
Cash Used for Financing Activities
Issuance of Capital Stock 71.25M 995.00K 101.55M 45.61M
Repayment of Long-Term Debt -8.96M -12.27M -2.73M 0.00
Repurchase of Capital Stock 0.00 0.00 0.00 0.00
Payment of Cash Dividends 0.00 0.00 0.00 0.00
Other Financing Charges, Net -28.00K -25.75M 4.02M -100.00K
Net Cash From Financing Activities 62.26M -37.03M 117.84M 61.72M
Effect of Exchange Rate Changes -7.00K 0.00 0.00 0.00
Net Change in Cash & Cash Equivalents 14.64M -24.52M 17.83M 26.64M
SGNT News

SGNT Sagent Pharmaceuticals Co

Analysts Ratings for SGNT

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 2 2 2 2
Moderate Buy 0 0 0 0
Hold 4 4 4 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET SGNT ANALYST REPORT

Brokerage Partners

SGNT Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs